A Clinical Intervention Study of Tangningtongluo on Diabetic Foot Ulcer
4 de marzo de 2022 actualizado por: Affiliated Hospital of Nantong University
Purpose and significance:With the increasing incidence of Diabetes mellitus (DM), the incidence rate of Diabetic Foot (DF) is raised. DF is a foot infection, ulceration and / or deep tissue destruction caused by nerve abnormalities and varying degrees of vascular lesions in DM patients. The high incidence, disability and mortality rate of DF make it urgent to explore new ways to improve the cure rate, reduce the burden and elevate the quality of life. Previous studies have confirmed that traditional Miao ethic medicine Tangningtongluo(TNTL) can improve the remission rate of diabetes mellitus and diabetic foot disease, but the clinical research evidence is not sufficient. This study aims to provide effective clinical evidence for the treatment of diabetic foot patients with TNTL by observing growth rate of wound, prognosis and outcome.
Methods: From September 2021 to March 2023, a total of 80 diabetic foot ulcer patients admitted to Department of Endocrinology and Metabolism at the Affiliated Hospital of Nantong University were recruited. Participants are randomized in a ratio of 1: 1: 1:1 into four treatment groups of 20 participants: (i) standardized western medicine treatment group, (ii) standardized western medicine treatment+TNTL tablet+TNTL cream group , (iii) standardized western medicine treatment+TNTL tablet group, and (iiii) standardized western medicine treatment+TNTL cream group. Treatment with TNTL tablets: the oral administration of TNTL tablets, 4 tablets each time, 3 times a day. Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing. Anthropometric parameters, serum biochemical index, glycosylated hemoglobin, urinary microalbumin/creatinine ratio, islet-specific autoantibodies(ISAs), fat mass, and islet β-cell function were measured. The healing stage of the wound surface and the growth degree of granulation tissue were graded, and the time required for wound repairing to each healing stage was observed.
Type of study: randomized controlled, prospective,intervention study.
Descripción general del estudio
Estado
Reclutamiento
Condiciones
Descripción detallada
From September 2021 to March 2023, a total of 80 diabetic foot ulcer patients admitted to Department of Endocrinology and Metabolism at the Affiliated Hospital of Nantong University were recruited.
Participants are randomized in a ratio of 1: 1: 1:1 into four treatment groups of 20 participants: (i) standardized western medicine treatment group, (ii) standardized western medicine treatment+TNTL tablet+TNTL cream group , (iii) standardized western medicine treatment+TNTL tablet group, and (iiii) standardized western medicine treatment+TNTL cream group.
Treatment with TNTL tablets: the oral administration of TNTL tablets, 4 tablets each time, 3 times a day.
Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
Anthropometric parameters, serum biochemical index, glycosylated hemoglobin, urinary microalbumin/creatinine ratio, islet-specific autoantibodies(ISAs), fat mass, and islet β-cell function were measured.
The healing stage of the wound surface and the growth degree of granulation tissue were graded, and the time required for wound repairing to each healing stage was observed.
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
80
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Jiangsu
-
Nantong, Jiangsu, Porcelana, 226001
- Reclutamiento
- Gu Yunjuan
-
Contacto:
- Gu Yunjuan, M.D/Ph.D
- Número de teléfono: +8615851207860
- Correo electrónico: desette@ntu.edu.cn
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Clinical diagnosis of Type 2 diabetes mellitus
- Clinical diagnosis of Diabetic Foot Ulcer
Exclusion Criteria:
- Type 1 diabetes mellitus(T1DM), special type of diabetes, gestational diabetes mellitus, drug-induced hyperglycemia
- TNTL allergy
- Chronic kidney failure（eGFR≤30ml/min/1.73cm2）, severe liver function damage (transaminase ≥ 3 times the normal value), acute or chronic pancreatitis, autoimmune disease, malignant tumors
- Recent acute complications of type 2 diabetes mellitus（ketoacidosis, hyperosmolar nonketotic diabetic coma, lactic acidosis etc.）or other emergency situations
- History of using glucocorticoids and immunosuppressants
- Mental illness and cognitive dysfunction or poor compliance, unable to take medication as required
- Malignant ulcer
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Standardized Western Medicine Treatment Group
All participants undergo a similar treatment protocol for the diabetic foot, based on the Infectious Diseases Society of America (IDSA).
|
Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
Otros nombres:
|
|
Experimental: Standardized Western Medicine Treatment +TNTL tablet+TNTL cream Group
Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day.
Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
|
Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
Otros nombres:
Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc.
It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.There are two dosage forms: tablet and cream.
Otros nombres:
|
|
Experimental: Standardized Western Medicine Treatment +TNTL tablet Group
Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day.
|
Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
Otros nombres:
Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc.
It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
Otros nombres:
|
|
Experimental: Standardized Western Medicine Treatment +TNTL cream Group
Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
|
Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
Otros nombres:
Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc.
It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Decrease area of wound healing due to Diabetic Foot Ulcer
Periodo de tiempo: 12 weeks
|
Assessment the decrease of whole area of diabetic foot ulcers.
The unit is square centimeters .
|
12 weeks
|
|
Decrease of depth of ulcer involve the deep fascia.
Periodo de tiempo: 12 weeks
|
Measurement of depth of ulcer involve the deep fascia.
The unit is millimeters.
|
12 weeks
|
|
Amputation Rate
Periodo de tiempo: 12 weeks
|
The difference of end-stage amputation rates between the experimental group and the control group were evaluated by the arterial and venous blood circulation of the lower limbs
|
12 weeks
|
|
Diabetic Foot Ulcer relapse rate
Periodo de tiempo: 12 weeks
|
The relapse of Diabetic Foot Ulcers is a common complication in the advanced stage of DFU.
The difference of treatment between the experimental group and the control group indicates that the prognosis is variability.
|
12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Fasting glucose
Periodo de tiempo: 12 weeks
|
10 hours after fasting peripheral blood glucose level, and the unit is mmol/L
|
12 weeks
|
|
2-H postload glucose
Periodo de tiempo: 12 weeks
|
2 hours after peripheral blood glucose level eating 75g glucose or 100g steamed bread, and the unit is mmol/L
|
12 weeks
|
|
BMI Index
Periodo de tiempo: 12 weeks
|
The calculation formula of Body Mass Index is: BMI = weight ÷ height 2. (weight in kilograms; height in meters.)
|
12 weeks
|
|
WHR Index
Periodo de tiempo: 12 weeks
|
Waist to hip ratio (WHR) = waist / hip.Waist circumference or minimum waist circumference shall be used for measurement, and evaluation of WHR is an important value to central obesity.
|
12 weeks
|
|
Islet B cell function
Periodo de tiempo: 12 weeks
|
The ability of islet B cells to secrete insulin was reflected by the level of C peptide, which is measured after fasting.
The unit is ng/dL .
|
12 weeks
|
|
interleukin-6(IL-6)
Periodo de tiempo: 12 weeks
|
Determine the level of interleukin-6(IL-6) in peripheral blood by ELISA, the unit is ng/L.
|
12 weeks
|
|
tumour necrosis factor-α(TNF-α)
Periodo de tiempo: 12 weeks
|
Determine the level of TNF-α in peripheral blood , the unit is ng/ml.
|
12 weeks
|
|
C-reactive protein(CRP)
Periodo de tiempo: 12 weeks
|
Determine the level of C-reactive protein(CRP) in peripheral blood , the unit is μg/L.
|
12 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
15 de enero de 2022
Finalización primaria (Anticipado)
30 de diciembre de 2022
Finalización del estudio (Anticipado)
31 de marzo de 2023
Fechas de registro del estudio
Enviado por primera vez
2 de septiembre de 2021
Primero enviado que cumplió con los criterios de control de calidad
2 de diciembre de 2021
Publicado por primera vez (Actual)
6 de diciembre de 2021
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
18 de marzo de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
4 de marzo de 2022
Última verificación
1 de septiembre de 2021
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Enfermedades de la piel
- Enfermedades del sistema endocrino
- Angiopatías diabéticas
- Úlcera en la pierna
- Úlcera de la piel
- Complicaciones de la diabetes
- Diabetes mellitus
- Neuropatías diabéticas
- Enfermedades de los pies
- Pie diabético
- Úlcera del pie
- Úlcera
Otros números de identificación del estudio
- TNTL on diabetic foot ulcer
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .